Target- |
MechanismIron replacements |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.Austria |
First Approval Date21 Mar 2012 |
/ Not yet recruitingPhase 2 An open label trial evaluating the pharmacokinetics and safety of an intravenously administered single dose of Feramyl® 200 mg, 500 mg or 1500 mg vs. Ferinject® 500 mg in patients suffering from anaemia following cardiac surgery - Feramyl® PK and safety trial in patients suffering from anaemia following cardiac surgery
/ Not yet recruitingNot Applicable An open label study on safety and pharmacokinetics of an intravenous administered single dose of Feramyl 200 mg in healthy blood donors compared to a single dose of Feramyl 1000 mg in IBD patients to evaluate dose dependency and kinetics after 1 hour infusion.
/ Not yet recruitingPhase 3 Open clinical study to determine the compatibility of Pyolysin®-Salbe in children aged between 0 and 17 years during the dermatological treatment of superficial wounds - Clinical study Pyolysin®-Salbe in children
100 Clinical Results associated with Serumwerk Bernburg AG
0 Patents (Medical) associated with Serumwerk Bernburg AG
100 Deals associated with Serumwerk Bernburg AG
100 Translational Medicine associated with Serumwerk Bernburg AG